BACKGROUND: Hypoxic pulmonary vasoconstriction (HPV) is impaired during inflammatory lung processes such as pneumonia or the acute respiratory distress syndrome. Voltage-gated potassium channels play a central role in mediating HPV. The aim of this study was to determine whether 4-aminopyridine (4-AP), a known voltage-gated potassium channel inhibitor, may restore HPV in sepsis. METHODS: The effects of 0.01, 0.1, and 1.0 mm 4-AP on HPV responsiveness were assessed in isolated lungs of untreated mice and of mice 18 h after lipopolysaccharide injection (20 mg/kg intraperitoneal Escherichia coli 0111:B4 lipopolysaccharide). HPV was quantified as the increase in perfusion pressure in response to hypoxic ventilation in percent of baseline perfusion pressure. Intrinsic pulmonary vascular resistance (R0) and pulmonary vascular distensibility (alpha) were determined by nonlinear regression analysis of pulmonary vascular pressure-flow curves generated during normoxic and hypoxic ventilation, respectively. RESULTS: HPV was impaired in lungs isolated from lipopolysaccharide-challenged mice. Addition of 4-AP to the perfusate did not alter HPV responsiveness in untreated mice but dose dependently restored HPV in endotoxemic mice. Analysis of pulmonary vascular pressure-flow curves revealed that 4-AP (1) counteracted the observed lipopolysaccharide-induced changes in alpha and R0 under normoxic conditions and (2) augmented the hypoxia-induced increase in R0 in lungs of endotoxemic mice. CONCLUSIONS: This study demonstrates that lipopolysaccharide-induced pulmonary vascular hyporesponsiveness to hypoxia can be restored by 4-AP in murine endotoxemia and, thus, may be a new therapeutic approach to treat patients with hypoxemia due to impaired HPV.
BACKGROUND:Hypoxic pulmonary vasoconstriction (HPV) is impaired during inflammatory lung processes such as pneumonia or the acute respiratory distress syndrome. Voltage-gated potassium channels play a central role in mediating HPV. The aim of this study was to determine whether 4-aminopyridine (4-AP), a known voltage-gated potassium channel inhibitor, may restore HPV in sepsis. METHODS: The effects of 0.01, 0.1, and 1.0 mm 4-AP on HPV responsiveness were assessed in isolated lungs of untreated mice and of mice 18 h after lipopolysaccharide injection (20 mg/kg intraperitoneal Escherichia coli 0111:B4 lipopolysaccharide). HPV was quantified as the increase in perfusion pressure in response to hypoxic ventilation in percent of baseline perfusion pressure. Intrinsic pulmonary vascular resistance (R0) and pulmonary vascular distensibility (alpha) were determined by nonlinear regression analysis of pulmonary vascular pressure-flow curves generated during normoxic and hypoxic ventilation, respectively. RESULTS: HPV was impaired in lungs isolated from lipopolysaccharide-challenged mice. Addition of 4-AP to the perfusate did not alter HPV responsiveness in untreated mice but dose dependently restored HPV in endotoxemic mice. Analysis of pulmonary vascular pressure-flow curves revealed that 4-AP (1) counteracted the observed lipopolysaccharide-induced changes in alpha and R0 under normoxic conditions and (2) augmented the hypoxia-induced increase in R0 in lungs of endotoxemic mice. CONCLUSIONS: This study demonstrates that lipopolysaccharide-induced pulmonary vascular hyporesponsiveness to hypoxia can be restored by 4-AP in murineendotoxemia and, thus, may be a new therapeutic approach to treat patients with hypoxemia due to impaired HPV.
Authors: Christoph Tabeling; Hanpo Yu; Liming Wang; Hannes Ranke; Neil M Goldenberg; Diana Zabini; Elena Noe; Adrienn Krauszman; Birgitt Gutbier; Jun Yin; Michael Schaefer; Christoph Arenz; Andreas C Hocke; Norbert Suttorp; Richard L Proia; Martin Witzenrath; Wolfgang M Kuebler Journal: Proc Natl Acad Sci U S A Date: 2015-03-17 Impact factor: 11.205
Authors: Maurizio Turzo; Karin Metzger; Felix Lasitschka; Markus A Weigand; Cornelius J Busch Journal: BMC Pulm Med Date: 2020-10-08 Impact factor: 3.317
Authors: Martin Wepler; Arkadi Beloiartsev; Mary D Buswell; Dipak Panigrahy; Rajeev Malhotra; Emmanuel S Buys; Peter Radermacher; Fumito Ichinose; Donald B Bloch; Warren M Zapol Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-11-04 Impact factor: 5.464
Authors: Liming Wang; Jun Yin; Hannah T Nickles; Hannes Ranke; Arata Tabuchi; Julia Hoffmann; Christoph Tabeling; Eduardo Barbosa-Sicard; Marc Chanson; Brenda R Kwak; Hee-Sup Shin; Songwei Wu; Brant E Isakson; Martin Witzenrath; Cor de Wit; Ingrid Fleming; Hermann Kuppe; Wolfgang M Kuebler Journal: J Clin Invest Date: 2012-10-24 Impact factor: 14.808
Authors: Hae Young Yoo; Amy Zeifman; Eun A Ko; Kimberly A Smith; Jiwang Chen; Roberto F Machado; You-Yang Zhao; Richard D Minshall; Jason X-J Yuan Journal: Pulm Circ Date: 2013-04 Impact factor: 3.017
Authors: Mario Kaßmann; István András Szijártó; Concha F García-Prieto; Gang Fan; Johanna Schleifenbaum; Yoland-Marie Anistan; Christoph Tabeling; Yu Shi; Ferdinand le Noble; Martin Witzenrath; Yu Huang; Lajos Markó; Mark T Nelson; Maik Gollasch Journal: J Am Heart Assoc Date: 2019-05-07 Impact factor: 5.501
Authors: Jun Yin; Liming Wang; Ning Yin; Arata Tabuchi; Hermann Kuppe; Gerhard Wolff; Wolfgang M Kuebler Journal: PLoS One Date: 2013-09-19 Impact factor: 3.240
Authors: Nora Jahn; Regis R Lamberts; Cornelius J Busch; Maria T Voelker; Thilo Busch; Marleen J A Koel-Simmelink; Charlotte E Teunissen; Daniel D Oswald; Stephan A Loer; Udo X Kaisers; Jörg Weimann Journal: Respir Res Date: 2015-09-29